[Pathological neocortical findings in patients with medication-resistant medial temporal lobe epilepsy submitted to

B Estupiñán-Díaz1, L M Morales-Chacón, L Lorigados-Pedre

  • 1Laboratorio de Anatomía Patológica, Centro Internacional de Restauración Neurológica, Ciudad de La Habana, Cuba. barbarae.diaz@infomed.sld.cu

Revista De Neurologia
|March 11, 2008
PubMed
Abstract

Insights

Medication-resistant epilepsy patients often have dual pathology. Surgical resection of the epileptogenic zone, guided by electrocorticography, leads to favorable outcomes in most cases.

Area of Science:

  • Neuroscience
  • Neuropathology
  • Epileptology

Context:

  • Medication-resistant medial temporal lobe epilepsy (MTLE) frequently presents with dual pathology, combining hippocampal sclerosis and focal cortical dysplasia (FCD).
  • Surgical intervention is often considered for patients with refractory MTLE.
  • Understanding the underlying histopathological changes is crucial for optimizing surgical outcomes.

Purpose:

  • To investigate the histopathological alterations in the neocortex of patients with medically refractory MTLE undergoing surgery.
  • To correlate these histopathological findings with the patients' pathological background and clinical course post-surgery.

Summary:

  • Histopathological analysis of neocortical tissue from 18 MTLE patients revealed dual pathology in 72.2% (13/18).
  • Focal cortical dysplasia (FCD) types 1a and 1b were the most common findings.
  • A significant association was observed between dual pathology and a history of early precipitating injury (p=0.04).
  • Post-surgery, 72.7% of patients with dual pathology achieved favorable outcomes (Engel class I) one year after tailored lobectomy.

Impact:

  • Identifies microscopic FCD-type alterations in the neocortex of MTLE patients.
  • Highlights the link between neocortical alterations, precipitating injuries, and epilepsy progression.
  • Demonstrates the efficacy of electrocorticography-guided tailored lobectomy in achieving favorable post-surgical outcomes for MTLE patients.